EUCTR2007-001890-27-ES进行中（未招募）不适用
Ensayo Clínico fase II aleatorizado, doble ciego, controlado con placebo, multicéntrico, para evaluar la eficacia y seguridad de ZACTIMA® en pacientes con Carcinoma papilar o folicular de Tiroides localmente avanzado o metastático que han fracasado al tratamiento con yodo radioactivo o que no son candidatos a recibirloA Randomized, Double Blind, placebo-controlled Phase II, Multi-Centre Study to Assess the Efficacy and Safety of Zactima™ in Patients with advanced or metastatic papillary or follicular Thyroid Carcinoma failing or unsuitable for Radioiodine therapy
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 135
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Provision of written informed consent prior to any study-related procedures.
- •2.Female or male aged 18 years and over.
- •3.Previously confirmed histological diagnosis of locally advanced or metastatic papillary or follicular thyroid carcinoma, without anaplastic component. Tumor sample available for centralized exploratory analysis.
- •4.Presence of one or more measurable lesions at least 1 cm in the longest diameter by spiral CT scan or 2 cm with conventional techniques.
- •5.Life expectancy of 12 weeks or longer.
- •6.WHO Performance status 0-2.
- •7.Able to swallow study medication.
- •8.Progressive disease following RAI131 or patient unsuitable for RAI131 after surgery.
- •9.Serum TSH<0.5mU/L.
- •10.Negative pregnancy test for female subjects of childbearing potential.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Brain metastases or spinal cord compression, unless treated at least 4 weeks before first dose and stable without steroid treatment for 10 days.
- •2.Major surgery within 4 weeks before randomization.
- •3.Prior chemotherapy within the last 4 weeks prior to randomization.
- •4.RAI131 therapy within 3 months in patients with radioiodine uptake.
- •5.Radiation therapy within the last 4 weeks prior to randomization (with the exception of palliative radiotherapy).
- •6.Serum bilirubin >1.5 x the upper limit of reference range (ULRR).
- •7.Creatinine clearance < 30 ml/min (calculated by Cockcroft-Gault formula).
- •8.Potassium <4.0 mmol/L despite supplementation; or above the CTCAE grade 1 upper limit.
- •9.Magnesium below the normal range despite supplementation or above the CTCAE grade 1 upper limit.
- •10.Serum calcium above the CTCAE grade 1 upper limit.
- •11.In cases where the serum calcium is below the normal range:
- •-The calcium adjusted for albumin is to be obtained and substituted for the measured serum value. Exclusion is to then be based on the calcium adjusted for albumin values decreasing below the normal limit. Corrected calcium = Ca + 0.8 X (4-serum albumin).
- •12.Alanine aminotransferase (ALT), aspartate aminotransferase (AST), or alkaline phosphatase (ALP) greater than 2.5 × ULRR, or greater than 5.0 × ULRR if judged by the investigator to be related to liver metastases.
- •13.Clinically significant cardiovascular event (eg myocardial infarction), superior vena cava [SVC] syndrome, New York Heart Association [NYHA] classification of heart failure =II within 3 months before entry, or presence of cardiac disease that in the opinion of the Investigator increases the risk of ventricular arrhythmia.
- •14.History of arrhythmia (multifocal premature ventricular contractions [PVCs], bigeminy, trigeminy, ventricular tachycardia or uncontrolled atrial fibrillation), which is symptomatic or requires treatment (CTCAE grade 3), , or asymptomatic sustained ventricular tachycardia. Subjects with atrial fibrillation controlled by medication are permitted.
- •15.Congenital long QT syndrome or 1st degree relative with unexplained sudden death under 40 years of age.
- •16.QT prolongation with other medications that required discontinuation of that medication.
- •17.Presence of left bundle branch block (LBBB).
- •18.QTc with Bazett’s correction unmeasurable or =480 msec on screening ECG (Note: If a subject has QTc interval =480 msec on screening ECG, the screen ECG may be repeated 2 times [at least 24 hours apart]. The average QTc from the three screening ECGs must be <480 msec in order for the subject to be eligible for the study). Patients who are receiving a drug that has a risk of QTc prolongation (see Appendix E for list of medications) are excluded if QTc is = 460 msec.
- •19.Hypertension not controlled by medical therapy (systolic BP greater than 160 millimeter of mercury [mmHg] or diastolic blood pressure greater than 100 mmHg).
- •20.Any concomitant medications that may cause QTc prolongation or induce Torsades de Pointes (see Appendix E for the lists of medications in Table 1 & Table 2) or induce CYP3A4 function.
- •21.Currently active diarrhea that may affect the ability of the patient to absorb the ZACTIMA or tolerate diarrhea.
- •22.Previous or current malignancies of other histologies within the last 5 years, with the exception of in situ carcinoma of the cervix, and adequately treated basal cell or squamous cell carcinoma of the skin.
- •23.Any unresolved chron
研究者
相似试验
进行中（未招募）
1 期
Ensayo clínico en fase II aleatorizado, doble ciego, controlado con placebo para estudiar la eficacia y la seguridad de bicalutamida con o sin deforolimus en varones con cáncer de próstata asintomático metastásico y resistente a la castración. A Phase IIA Randomized, Double-blind, Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Bicalutamide with or without Deforolimus in Men with Asymptomatic, Metastatic Castrate-Resistant Prostate CancerCancer de prostata metastasico Metastatic prostate cancerMedDRA version: 9.1 Level: LLT Classification code 10036909 Term: Prostate cancer metastaticEUCTR2008-000422-39-ESMerck & Co., Inc.156
进行中（未招募）
不适用
Ensayo clínico fase II, aleatorizado, triple ciego, controlado intraindividualmente con placebo, para evaluar la eficacia y seguridad de la rapamicina tópica sola o asociada a láser de colorante pulsado en pacientes con síndrome de Sturge-WeberEUCTR2010-024078-20-ESInstituto Científico y Tecnológico de Navarra
进行中（未招募）
1 期
Ensayo en fase II, aleatorizado, doble ciego, controlado con placebo para evaluar la eficacia y la seguridad de ZD6474 en combinación con Arimidexâ?frente a Arimidexâ?solo como tratamiento de segunda línea en pacientes con cáncer de mama avanzado (CMA) hormonosensible (receptores de estrógeno positivos y/o receptores de progesterona positivos).Cáncer de mama avanzado (CMA) hormono sensible (ER+ve y/o PR+ve)EUCTR2005-003591-38-ESAstraZeneca AB64
进行中（未招募）
1 期
Ensayo Clínico fase IIa, doble ciego, controlado con placebo para evaluar la Eficacia de MEDI 563 en pacientes con Enfermedad Pulmonar Obstructiva Crónica de moderada a grave y eosinofilia en esputoA Phase 2a, double blind, placebo controlled study to evaluate the efficacy of MEDI-563 in subjects with moderate to severe COPD and sputum eosinophiliaEnfermedad Pulmonar Obstructiva Crónica y eosinofilia en esputoChronic obstructive pulmonary disease and Sputum EosinophiliaMedDRA version: 12.1Level: LLTClassification code 10010952Term: COPDEUCTR2010-020127-52-ESAstraZeneca AB101
进行中（未招募）
1 期
Estudio de fase 2, aleatorizado, a doble ciego y controlado con placebo para evaluar la seguridad y eficacia de FOLFIRI en combinación con AMG 479 o AMG 655 en comparación con FOLFIRI en el tratamiento de segunda línea del carcinoma colorrectal metastásico con KRAS mutado.A Phase 2, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safetyand Efficacy of FOLFIRI in Combination With AMG 479 or AMG 655 Versus FOLFIRI for the Second-line Treatment of KRAS-mutant Metastatic Colorectal CarcinomaEUCTR2008-005301-19-ESAmgen Inc150